trending Market Intelligence /marketintelligence/en/news-insights/trending/l0uxcwy9xnbkxygcaut0uw2 content esgSubNav
In This List

J&J, Astex's bladder cancer drug gets US FDA breakthrough therapy designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


J&J, Astex's bladder cancer drug gets US FDA breakthrough therapy designation

The U.S. Food and Drug Administration granted the breakthrough therapy designation to a medicine known as erdafitinib.

Erdafitinib was discovered by Johnson & Johnson's Janssen Pharmaceutical Cos. and privately held Astex Pharmaceuticals, Inc. as part of a partnership. It is being studied to treat urothelial cancer, which is most frequently in the bladder and the sixth most common type of cancer in the U.S.

The designation was granted based on data from a phase 2 clinical trial and will help to expedite developing the treatment.